FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on <i>FGFR1</i>/<i>3</i> mRNA Expression
Bayer
Cora N Sternberg; Daniel P Petrylak; Joaquim Bellmunt; Hiroyuki Nishiyama; Andrea Necchi; Howard Gurney; Jae-Lyun Lee; Michiel S van der Heijden; Eli Rosenbaum; Nicolas Penel; See-Tong Pang; Jian-Ri Li; Xavier García Del Muro; Florence Joly; Zsuzsanna Pápai; Weichao Bao; Peter Ellinghaus; Chengxing Lu; Mitchell Sierecki; Sabine Coppieters; Keiko Nakajima; Tatiane Cristine Ishida; David I Quinn